GlassScriptPhysician profile
Egon F Dzintars
NPI 1770530438
$3,673.66
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,378 · 2020: $553 · 2021: $1,305 · 2022: $437.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $564.80 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $422.79 | 2019-2022 | |
| Lilly USA, LLC | $399.28 | 2019-2022 | |
| Pfizer INC. | $397.41 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $286.53 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $282.45 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $253.11 | 2019-2021 | |
| Novo Nordisk INC | $241.87 | 2019-2022 | |
| Glaxosmithkline, LLC. | $156.03 | 2019-2022 | |
| Amarin Pharma, INC. | $123.19 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $117.15 | 2020-2022 | |
| Eisai INC. | $61.48 | 2020-2021 | |
| Abbvie INC. | $51.18 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $49.33 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.66 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $46.99 | 2019-2021 | |
| Astellas Pharma US INC | $33.64 | 2022 | |
| Allergan, INC. | $23.20 | 2019 | |
| Abbott Laboratories | $22.66 | 2021 | |
| Grifols USA, LLC | $22.13 | 2019-2020 | |
| Biogen, INC. | $16.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.59 | 2021 | |
| Daiichi Sankyo INC. | $14.26 | 2022 | |
| Hologic Sales and Service, LLC | $13.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.68 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Egon Dzintars listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.